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Chairman Abdul Manaf bin Ali, Ph.D. 
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Ever since hybridoma technology was introduced b y  Kohler 
and Milstein in the 70's, numerous efforts have been undertaken 
to produce monoclonal antibodies (MAbs )  against mammary cancer 
cells. However, even to this day, all the MAb s  produced still 
possess cross-reactivities toward other types of cancerous cells 
and also normal mammary cells. 
In this study, the breast cancer eel} line MCF-7 was used as 
an immunogen to raise MAb against mammary cancer cells. Fusion 
between lymphocytes sensitised with MCF-7 cell line and myeloma 
cells, SP2, was performed using 50% of polyethylene glycol ( PEG).  
The hybridoma secreting MAb against MCF-7 cell line was selected 
using cell-ELISA technique. Limiting dilution of five times was 
performed to yield a stable hybridoma clone secreting the MAb. 
xv 
The selected clone, C2E7 , which secreted MAb of the Igt-1 class and 
lamda light chains was chosen for further studies. 
MAb secreted by C2E7 was found to react with an antigenic 
determinant located in the cytoplasm of the MCF-7 cell line. 
Immunocytochemical studies showed that apart from the MCF-7 cell 
line, the antigenic determinant was also present in mammary 
cancer cell line of T47-D. Weak cross-reactivities were also 
observed against cell lines Panc-l and Ova-3. Immunohistochemical 
studies using the immunoperoxidase technique showed that staining 
occurred in the cytoplasmic region of all mammary lobular 
carcinoma and 90% of mammary ductal carcinoma examined. Staining 
was also found in 50% of mammary fibroadenoma cases studied. On 
the contrary, no staining of tissues was found in uterine 
leiomyoma, stomach showing intestinal metaplasia, cervical 
carcinoma, tonsillitis, neurofibroma, ductal papilloma of the breast 
and normal mammary tissues. Biochemical studies showed that the 
antigenic determinant on the MCF-7 cell line with reactivity 
towards MAb C2E7 was composed of endopeptide chain having 
arginine and lysine as the side chains, and possessed a specific 
conformational order which was disrupted when the determinant 
was electrophoresed on SDS-PAGE. Consequently, characterisation 
of the determinant using Western Blotting technique could not 
be performed. 
xvi 
The hybridoma clone C2E7 was able to grow and proliferate 
in serum-free medium of EDRF supplemented with ITES. 
Purification technique using a combination of ammonium sulphate 
precipitation and gel filtration on Sepharose 6B enabled the 
separation of IgM from MAb secretion of C2E7 hybridomas cultured 
in serum-free medium. 
xvii 
Abstrak tesis yang dikemukakan kepada Senat 
Universiti Pertanian Malaysia sebagai memenu hi syarat 
keperluan untuk Ijazah Master Sains 
PENGHASILAN, PEMBENTUKAN DAN PENCIRIAN 
ANTIBODI MONOKLON 
TERHADAP TITISAN SEL BARAH BUAH DADA MANUSIA ( MCF-7) 
Oleh 
ONG BOO KEAN 
Oktober, 1995 
Pengerusi Abdul Manaf bin Ali, Ph.D. 
Fakulti Sains Makanan dan Bioteknologi 
Semenjak teknologi hibridoma diperkenalkan Kohler dan 
Milstein pada tahun 70'an, pelbagai u saha telah dilakukan untuk 
menghasilkan antibodi monoklon (MAb) terhadap sel barah buah 
dada. Namun demikian, sehingga kini, hampir semua MAb yang 
telah dihasilkan itu masih mempunyai tindak-balas silang terhadap 
sel barah jenis lain dan juga sel normal buah dada. 
Dalam kajian ini, titisan sel barah buah dada, MCF-7 telah 
digunakan sebagai immunogen dalam penghasilan Mab terhadap sel 
barah buah dada. Perlakuran antara sel limfosit yang telah 
diaruhkan dengan MCF-7 dan sel mieloma, SP2 dilakukan dengan 
50% PEG. Teknik sel-ELISA telah digunakan untuk memilih 
hibridoma yang merembes antibodi terhadap titisan sel MCF-7. 
Pencairan terhad sebanyak lima kali dilakukan, agar klon 
xviii 
hibridoma yang stabil dalam rernbesan MAb diperolehi. Seterusnya, 
hibridoma klon C2E7 yang merembes MAb kelas IgM dan rantai 
ringan lamb da telah dipilih untuk kajian selanjutnya. 
MAb dari C2E7 didapati bertindak dengan suatu penentu 
antigenik di sekitar sitoplasma titisan sel MCF-7. Kajian 
immunositokimia juga menunjukkan, selain di  titisan sel MCF-7, 
penentu antigenik ini juga hadir di titisan sel barah buah dada 
T47-D. Tindak balas silang yang lemah juga didapati berlaku 
terhadap titisan sel Panc-l dan Ova-3. Dalam kajian 
immunohistokimia dengan menggunakan teknik imrnunoperoksidase, 
didapati pewarnaan berlaku di kawasan sitoplasma pad a sernua tisu 
barah buah dada jenis karsinoma lob ular dan 90% daripada tisu 
barah buah dada jenis karsinoma lobular yang telah diuji. 
Pewarnaan juga didapati pad a 50% daripada kes fibroadenoma buah 
dada yang diuji. Sebaliknya, tiada sebarang pewarnaan berlaku 
pada tisu seperti uterine leiomyoma, karsinoma servik, tonsillitis, 
neurofibroma, perut menunjukkan intestinal metaplasia, duktal 
papilloma buah dada dan juga tisu normal buah dada. Ujian 
biokimia menunjukkan, penunjuk antigenik di titisan sel MCF-7 
yang ditindak ole h MAb C2E7 , terdiri dari rantai endopeptid 
dengan arginin dan l ysin sebagai rantai sisi serta berada dalam 
keadaan konformasi ,>pesifik. Konformasi spesifik ini akan beru bah, 
andai kata ianya dielektroforeskan da]am SDS-PAGE. Oleh yang 
demikian, kaedah Western Blotting tidak dapat digunakan dalarn 
pencirian penentu antigenik tersebut. 
xix 
Hibridoma klon C2E7 berupaya hidup dan melakukan 
pembahagian sel dalam medium bebas serum, ERDF yang ditambah 
dengan ITES. Teknik penulenen yang melibatkan kombinasi 
pemendakan ammonium sulfat dan penurasan gel Sepharose 6B, 
membolehkan IgM, hasil rembesan hibridoma C2E7 yang dikultur 




Today, cancer is a major public health problem ( Lim, 1991). 
Globally, out of the fifty million deaths that occur annually, five 
million is attributed to cancer. The World Health Organisation 
estimated that, by the year 2000, this figure will increase to eight 
million whereby 5 to 25% of this number is due to breast cancer 
(Management, 1994). The incidence of breast cancer is high in most 
of the industrialised and developed countries (Harris et a1., 1992). 
In the United States, breast cancer is the leading cause of death 
among women who are about forty to fifty-five years of age. The 
incidence rate of this disease has increased steadily, since formal 
tracking of such cases through cancer registries began in the 
1930's. These incidences and mortality rates indicate that annually 
out of the 12% of American women diagnosed of having breast 
cancer, 3.5% of them will die of the disease (Harris et a1., 1992). 
In addition, according to Baum et a!. (1991), about one in every 
12 women in the United Kingdom will eventually develop this 
disease. Breast cancer is also one of the most common type of 
malignancy among women in Malaysia. About 1200 new cases of 
breast cancer are reported annually, Statistical data from the 
National Cancer Registry showed that cancer of the breast 
accounted for 10 and 18% of the total reported cancer and total 
female cancer cases respectively (Management, 1994). 
1 
2 
Basically, death as a result of breast cancer is due to the 
distant spreadin� or metastasis of malignant tumour cells from the 
breast to the other vital organs of the body like the liver, lungs, 
bone and brain ( Rosai, 1989). The progress of cancer can 
clinicopathologically be divided into four stages, namely, Stage I, 
II, III and IV (Chandrasoma and Taylor, 1991). Statistics showed 
that a patient suffering from Stage I of the disease and having 
a mass of less than 5 em localised in the breast has 85% of the 5 
year survival rate. However, patients with Stage IV of the disease 
where distant metastases have occurred, have only 10% of the 5 
year survival rate ( Chand rasoma and Taylor, 1991 ).  Therefore, 
early detection of breast cancer is very important because the 
smaller the lesion, the greater is the likelihood of cure. 
The detection and diagnosis of breast cancer is dependent 
upon the ability to discriminate between normal and neoplastic 
tissues. At present the histologic examination of a biopsy of a 
tumour mass is the most definitive diagnostic method of breast 
cancer ( Chandrasoma and Taylor, 1991). For almost a century, 
routine histopathological diagnosis has been based upon the 
examination of haematoxylin and eosin stained paraffin embedded 
tissue sections. Although a majority of the tissues received in 
routine histopathology labora.tories can be reliably diagnosed in 
this way, there are a nu mber of cases whereby a firm diagnosis 
cannot be made on morphological grounds alone (Gatter et aL, 
1982 ) .  To overcome such diagnostic problems diagnosis based on 
3 
immunohistological staining techniques were introduced. This 
approach although of genuine diagnostic value in some cases, has 
been limited in its scope by the relatively small number of tissue 
antigens which could be detected with conventional antisera. 
However, with the advent of hybridoma technology ( Kohler and 
Milstein, 1975), the range of antigenic constituents which can be 
detected by immunohistological techniques in human tissue has 
been dramatically expanded (Gatter et aL, 1982). 
Several attempts to establish monoclonal antibodies (MAbs) 
specifically towards antigenic constituents in the breast cancer 
have been reported (Schlom et al., 1 980; Taylow-Papadimitriou et 
aL, 1981; Foster et aL, 1 982; Cordell et aL, 1985; Pancino et 81, 
1989; Peterson et aL, 1990; Pancino et aL, 1991; Nuti et aL, 1992; 
Modjtahedi et aL, 1993). These MAbs differed in their binding 
capacities and their relative abilities to be sensitive and specific 
in recognising malignant cell lines as well as tissues of mammary 
origin. However, most of the reported MAb that react primarily 
with human breast carcinoma also showed reactivities towards 
other tumours and have considerable cross reactivities with normal 
human tissues. Consequently, to date, no MAb has yet been 
conclusively proven to be tumour specific for human breast 
carcinoma (Yuan et aL, 1982; Plessers et aL, 1 990; Blottiere et ai:, 
1991 ). 
Thus, the objectives of this study are : 
a) to produce murine MAb against breast cancer cell line 
MCF-7; 
b) to characterise the selected hybridoma clones; and 
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c) to cultivate a selected hybridoma clone in serum-free 
media and purify the MAb produced. 
